Notably, in vivo experiments demonstrated that EC@HNA treatment effectively decreased Treg cell levels while increasing CD8+ T cell proportions in PCa tissues, accompanied by downregulation of IL-10 and TGF-β expression. The gene discussed is CD8A; the disease is posterior cortical atrophy.